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Abstract  1 
Primary aldosteronism (PA), characterized by the inappropriate and excessive 2 
adrenal secretion of aldosterone, is the most common cause of secondary 3 
hypertension; PA has been shown to increase cardio- and cerebro-vascular risks 4 
in comparison with essential hypertension. PA is a multi-faceted disease, which 5 
comprises unilateral forms, benefitting from surgical treatment, and bilateral 6 
forms, which are best managed medically; PA is more frequently sporadic but in 7 
some cases displays a familial transmission pattern. For these reasons, it is 8 
important to diagnose PA early on and correctly distinguish and manage its 9 
different forms. 10 
In this review, we analyze the different forms of PA, with attention on the 11 
diagnostic pathway and the genetics of the disease.  12 
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Introduction 1 
Primary aldosteronism (PA) is defined as a syndrome, characterized by an 2 
inappropriate secretion of aldosterone, independent of the renin-angiotensin 3 
system and of sodium homeostasis. PA prevalence increases with blood pressure 4 
severity reaching up to 20% in patients with resistant hypertension [1,2]. Recent 5 
studies have also uncovered wider effects of aldosterone that go beyond BP, and 6 
affect a number of different target organs, in particular determining higher cardio- 7 
and cerebro-vascular risks in PA patients as compared to essential hypertensives 8 
with a similar risk profile  [3,4].  9 
Therefore, early detection of PA, is fundamental to best manage short and long-10 
term complications of this condition. 11 
The two most common forms of PA are the aldosterone-producing adenoma 12 
(APA), which accounts for 30-35% of all cases, and the bilateral adrenal 13 
hyperplasia (BAH), the most common PA subtype accounting for 65-70% of PA 14 
patients [5]. The therapeutic approaches are different depending from the 15 
subtypes, surgical for unilateral PA forms and medical treatment with 16 
mineralocorticoid receptors (MR) antagonists for BAH [5]. It should be noted that 17 
a relevant proportion of patients with unilateral PA, previously considered affectd 18 
by APA, display a moltinodular unilateral adrenal hyperplasia with one or more 19 
nodules expressing CYP11B2 with immunohistochemistry evaluation  [6,7]. 20 
These two forms of PA, both sporadic, together comprise the vast majority of all 21 
PA cases; less common, but nonetheless important in the diagnostic pathway, are 22 
the four familial forms. Recognition of these is important not only in the treatment 23 
of patient, but also in the screening of first-grade family members.  24 
 4 
In this manuscript we will review the subtype diagnosis of sporadic and familial 1 
PA. 2 
 3 
Diagnosis 4 
Diagnosis of PA is made by a screening test using the aldosterone to renin (or 5 
plasma renin activity ratio) [5]. Population with increased risk of PA that should 6 
be screened and the relationships and characteristics of different aldosterone and 7 
renin assay are described elsewhere  [8-10]. Confirmation of the suspicion of PA 8 
is made by one of four confirmatory/exclusion tests: the intravenous saline 9 
loading test, the oral saline loading test, the fludrocortisone-suppression test and 10 
the captopril challenge test. Characteristics and performance of the different 11 
confirmatory tests are discussed elsewhere  [5,11]. 12 
 13 
Imaging techniques and steroid measurements 14 
Once PA is confirmed, patients should undergo contrast-enhanced computed 15 
tomography (CT) scanning evaluation of the adrenal glands  [5,12]  as a first exam. 16 
CT findings can vary, from bilateral hyperplasia, to unilateral hyperplasia, to 17 
unilateral or bilateral micro and macro-nodules (diameter < 1 cm or > 1 cm). 18 
Lesions bigger than 4 cm are suspicious for the rare but deadly adrenal carcinoma  19 
[5]. CT displays several limitations: even using fine-cuts, CT may fail at identifying 20 
micro-APAs; moreover, it does not provide information on the functional role of 21 
the nodules, which can be especially crucial when bilateral lesions are observed  22 
[13].  23 
 5 
Other imaging techniques are available: the Endocrine Society approves magnetic 1 
resonance as an alternative to contrast CT, though it admittedly provides a lower 2 
quality of space resolution, and lower specificity  [5].  3 
Among functional imaging, 131I-6-iodomethyl-19-norcholesterol scintiscan has 4 
been abandoned; a more recent technique is the 11C-metomidate positron 5 
emission tomography (PET)-CT scan, that could be considered an alternative to 6 
AVS when this is unsuccessful, but that display a lower sensitivity and specificity 7 
that makes it not suitable to substitute AVS routinely  [14]. One of the limits of 8 
metomidate is its low selectivity for CYP11B1 over CYP11B2. For this reason, a 9 
Japanese group has tested a new, more CYP11B2-specific tracer, 18F-CDP2230. 10 
However, this new technique needs to be tested in a prospective trial in 11 
comparison with AVS  [15].  12 
An additional instrument in the diagnosis of APA versus BAH has been suggested 13 
with the measurement of the so-called "hybrid" steroids 18-oxocortisol (18oxoF) 14 
and 18-hydroxycortisol (18OHF), that are produced in large amount in a 15 
consistent proportion of APA compared to BAH and incidentalomas  [16,17]. 16 
Recently, through a more complete steroid profiling using liquid chromatography 17 
- tandem mass spectrometry (LC-MS/MS) to simultaneously measure 7 different 18 
adrenal steroids, it was possible to distinguish APA from BAH in a consistent 19 
proportion of cases and to identify those APA with a specific somatic genetic 20 
alteration  [18,19]. If this results will be confirmed in large prospective studies, 21 
steroid profiling by LC-MS/MS promise to be a preliminary test in order to identify 22 
PA patients with high probability of unilateral PA, thus reducing significantly the 23 
requirement for AVS procedures.   24 
 25 
 6 
Adrenal venous sampling 1 
Adrenal venous sampling, or AVS, is widely recognized as the gold standard 2 
technique in the distinction of unilateral from bilateral PA  [5,12]. In a review of 3 
950 cases, imaging technique (either CT scanning or magnetic resomnance) 4 
resulted in a wrong diagnosis in around 38% of cases compared to AVS  [20]. CT 5 
scanning can suggest inappropriate adrenalectomy in patients with BAH and 6 
unilateral nodule, or miss the opportunity of cure by adrenalectomy in cases of 7 
unilateral PA and bilateral nodules (with only one having secretory activity) or 8 
normal appearing adrenals and undetected micro-APA  [5,20]. The main pitfall of 9 
CT scanning is the lack of a proper identification of secretory activity of detected 10 
nodules; different parameters have been suggested, such as densitometry and 11 
contrast wash-out, but neither has been proven to provide definite answers in the 12 
distinction between secreting lesions and incidentalomas  [5,21]. Therefore, when 13 
adrenalectomy is not contraindicated because of comorbidities, AVS should 14 
always be suggested as the only reliable technique for PA subtype diagnosis  15 
[5,22].  16 
AVS is a complicated procedure, which not only requires an expert operator, but 17 
also an adequate preparation of the patient. In the 4-6 weeks leading to the 18 
procedure, it is suggested to treat hypertension with alpha-blockers and non-19 
dyhidropyridine calcium channel blockers, as they display the least influence on 20 
the renin-angiotensin system; if these drugs are not sufficient to reach the desired 21 
blood pressure control, beta-blockers, ACE-inhibitors and angiotensin-receptors 22 
blockers can be considered, while drugs such as thiazides, loop diuretics, 23 
amiloride and mineralocorticoid receptors antagonists should be avoided since 24 
they affect AVS results and interpretation.  Potassium levels should be kept within 25 
 7 
normal range  [22]. AVS can be performed both under basal or during cosyntropin 1 
infusion with similar results  [23]. Pro and cons of the two procedures are 2 
described elsewhere  [22]. 3 
During AVS a catheter is inserted percutaneously in a femoral vein and, through 4 
the use of contrast medium and fluoroscopy, the adrenal veins are singled out, and 5 
blood is gently drawn. Procedure techniques can be challenging, and an expert 6 
operator is required, as success rates can vary between 44% and 96%, according 7 
to the radiologist expertise  [22,24,25].   8 
Left adrenal vein cannulation is relatively easy, as the vein joins the inferior 9 
phrenic vein to create a common vessel that drains into the left renal vein. Right 10 
adrenal vein, on the other hand, creates a very sharp angle in its emergency 11 
directly into the inferior vena cava, which can be challenging to cannulate even for 12 
an expert radiologist  [24,25]. To avoid potential errors determined by blood 13 
dilution during adrenal veins cannulations, aldosterone values are always 14 
“corrected” by cortisol since it is considered that this hormone is equally produced 15 
from the two adrenals in PA patients  [5,22]. 16 
Cortisol measurement is also used to determine the correct cannulation of the 17 
adrenal veins. The two most important parameters measured during AVS are are 18 
the selectivity index (SI), which is the ratio between cortisol in the adrenal vein 19 
and cortisol in a peripheral vein (Table 1): this provides information about the 20 
adequacy of cannulation of the adrenal vein; and the lateralization index (LI) 21 
which determine the presence or not of a lateralization of aldosterone secretion. 22 
It is calculated as the ratio between cortisol-corrected aldosterone levels in one 23 
adrenal compare to the contralateral. A result of LI> 4 is diagnostic for unilateral 24 
 8 
PA (Table 1). A LI <3 is diagnostic for BAH. For LI between 3 and 4 other clinical 1 
parameters should be taken into account for final decision  [5,21,26].  2 
Another AVS parameter is the contralateral ration, that is the cortisol-corrected 3 
aldosterone ratio from the non-dominant adrenal vein in comparison with the 4 
peripheral vein (Table 1). A recent study has demonstrated that a contralateral 5 
suppression (i.e. a contralateral ratio <1) is not necessary to obtain cure or 6 
significant improvement of blood pressure levels after adrenalectomy  [27].  7 
AVS requires an experienced radiologist with an expertise in endovascular 8 
procedures, in order to minimize risks, most commonly the rupture of an adrenal 9 
vein during the procedure. The multi-centric study AVIS showed an inverse 10 
correlation between the experience of the radiologist and numbers of procedures 11 
done and the chance of complications  [28]. The most serious complication of AVS 12 
is adrenal hemorrhage. A retrospective study analyzed 24 cases of adrenal 13 
hemorrhage in patients who underwent AVS in 6 different referral centers; of 14 
these, the majority involved the right adrenal, coherent with the difficulty in the 15 
right adrenal vein cannulation and were more frequent in older patients  [29]. 16 
Interestingly, among all the analyzed cases, only one needed long-term 17 
corticosteroid replacement therapy for adrenal insufficiency. All hemorrhages 18 
were minor, and controlled by medical therapy without the need for new surgery 19 
or blood transfusions  [29].  20 
 21 
Genetics of PA 22 
Familial hyperaldosteronism (FH) account for up to 5-6% of all PA cases   [30,31]. 23 
The first form of FH to be discovered is also named glucocortidoid-remediable 24 
aldosteronism (GRA, or FH-I), which is caused by the creation of a chimeric gene 25 
 9 
from the fusion of the promoter region of the 11β-hydroxylase gene CYP11B1 with 1 
the coding region of the aldosterone synthase gene, CYP11B2   [32,33]  (Table 2). 2 
This determines a regulation of aldosterone production under the very active 3 
CYP11B1 (encoding 11-hydroxylase) promoter, which is regulated by ACTH. 4 
Patients with GRA usually present hypertension in the first two decades of their 5 
lives, and an increased risk of cerebral hemorrhage; moreover they show high 6 
levels of hybrid steroids. Transmission is autosomal dominant, and the disease, 7 
once diagnosed, can be easily managed by administration of low doses of 8 
glucocorticoids, often associated with mineralocorticoid receptor blockers  [34].  9 
FH-II is clinically undistinguishable from sporadic PA, and it is diagnosed by the 10 
familial pattern of the disease. Its genetics basis is still unknown, though a linkage 11 
to chromosome 7p22 has been suggested  [35,36]. It is conceivable that more 12 
types of genetic alterations are responsible for this condition (Table 2).   13 
FH-III is has been recently described by Choi in 2011  [37]. This disease is 14 
characterized more frequently by very early onset of severe hypertension and 15 
hyperaldosteronism that require bilateral adrenalectomy in most cases. FH-III is 16 
determined by gain-of-function mutations of KCNJ5 which KCNJ5 encodes for the 17 
potassium inwardly-rectifying channel Kir 3.4  [34] (Table 2); the mutations cause 18 
the channel to lose its selectivity for potassium, allowing large quantities of 19 
sodium to enter the cell, thus causing a membrane depolarization and the 20 
activation of voltage-gated calcium channels, with calcium influx into the cell, and 21 
activation of the cascade that results in aldosterone overproduction  [38]. It should 22 
be noted, that cases with more mild phenotypes have been described  [34,39,40].  23 
Primary aldosteronism with seizures and neurological abnormalities (PASNA) is 24 
an extremely severe form of PA, caused by a germline mutation in CACNA1D, which 25 
 10 
encodes a voltage-gated L-type calcium channel (Table 2); the mutations result in 1 
channel activation at less depolarized potentials, which in turn causes calcium 2 
influx and aldosterone production  [41,42]. Only two cases have been diagnosed 3 
so far: both patients were diagnosed at a very young age from healthy parents; it 4 
is believed that their neurological impairment is so severe not to allow affected 5 
individuals to reproduce. Therefore, this condition is considered not-familial 6 
despite the genetic cause and is expected to be caused only by de novo mutations. 7 
The latest discovery in familial forms is FH-IV, described by Scholl et al. in 2015  8 
[43]: FH-IV is caused by a germline mutation in another voltage-gated calcium 9 
channel gene, CACNA1H, highly expressed in the zona glomerulosa (Table 2). All 10 
index cases had PA and severe hypertension diagnosed by the age of 10 years, but 11 
without neurological abnormalities. Inheritance of FH-IV is autosomal dominant, 12 
though with incomplete penetrance, as carrier parents did not show the same 13 
severe hypertension as the index cases  [44] and also normotensive individuals 14 
with the mutation were observed.  15 
Intriguingly, mutations in KCNJ5 and CACNA1D were also described as somatic 16 
mutations in sporadic APAs  [42,45]. Other somatic mutations in genes 17 
responsible for aldosterone overproduction (ATP1A1 and ATP2B3) or involved in 18 
cell proliferation (CTNNB1) have also been described but without evidence of 19 
similar alterations responsible for familial forms   [46,47].  20 
PA patients with APA carrying mutations display in some cases specific steroid 21 
profiles that may help clinicians in the decision making process of PA subtype 22 
diagnosis  [18].  23 
 11 
Genetic basis for sporadic BAH are less understood for the difficulty of studying 1 
adrenal glands from this patients. In some cases, KCNJ5 mutations have been 2 
described, not associated to FH-III  [48].  3 
Heterozygous germline mutations in the armadillo repeat containing 5 gene 4 
(ARMC5) have been shown in patients with hypercortisolism due to sporadic 5 
primary bilateral macronodular adrenal hyperplasia  [49] and were also described 6 
in observed in African-American PA patients  [50] but not in a cohort of Caucasian 7 
BAH patients  [51]. 8 
 9 
Conclusions 10 
PA is a multi-faceted disease, which can lead to severe cardio- and cerebro-11 
vascular complications in affected patients. Different subtypes of disease benefit 12 
from different treatment options, and should therefore be carefully distinguished, 13 
in order to ensure the best management for the patients. 14 
 15 
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AVS Indices Measurement Clinical use Cut-offs 
 
Selectivity 
index (SI)  
 
Cortisoladrenal vein  
Cortisolperipheral vein 
 
Adequacy of 
cannulation of 
the adrenal 
veins 
SI> 3 = 
adrenal vein 
correctly 
cannulated 
Lateralisation 
index (LI) 
 
Aldosterone/Cortisoladrenal vein 
                                                                                                                 
Aldosterone/Cortisolcontralateral 
adrenal vein 
 
Differentiate 
unilateral from 
bilateral PA 
LI > 4 = 
unilateral PA 
LI <3 = 
bilateral PA 
Contra-lateral 
ratio (CLR) 
 
Aldosterone/Cortisolnondominant 
adrenal vein     
                                                                                                       
Aldosterone/ Cortisolperipheral 
vein  
 
Retro-inhibition 
of aldosterone 
secretion in the 
non-dominant 
adrenal gland  
CLR <1 and 
LI between 3 
and 4 = 
unilateral PA 
 10 
Table 1. Calculation and clinical use of AVS indices 11 
 FH-I FH-II FH-III FH-IV 
Gene Hybrid 
CYP11B1/B2 
Unknown 
Linkage at 7p22 
KCNJ5 CACNA1H 
Transmission AD AD AD AD 
Incomplete 
penetrance 
Severity of 
hypertension 
Normotension 
to resistant 
Normotension 
to resistant 
Grade II to 
resistant 
hypertension 
Normotension 
to resistant 
 20 
u-18oxoF 
u-18OHF 
Elevated Not elevated Mildly to 
extremely 
elevated 
Normal 
Aldosterone 
response to 
dexamethasone 
Complete 
suppression 
Partial 
reduction or no 
change 
Paradoxical 
increase (in 1 
family) 
Suppression in 
1 patient 
Adrenal CT 
scanning/Adrenal 
pathology 
Normal adrenal 
glands 
BAH or APA Bilateral 
hyperplasia or 
normal 
adrenals 
Marked zona 
glomerulosa 
hyperplasia (in 
1 patient) 
 1 
Table 2. Familial forms of primary aldosteronism. FH-I = Familial 2 
Hyperaldosteronism type 1; FH-II = Familial Hyperaldosteronism type II; FH-III = 3 
Familial Hyperaldosteronism type III; FH-IV = Familial Hyperaldosteronism type 4 
IV; AD = autosomal dominant; CCBs = Calcium Channel Blockers; BAH = Bilateral 5 
Adrenal Hyperplasia; APA = Aldosterone Producing Adenoma 6 
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